PMID: 6989483Apr 15, 1980Paper

Factors related to length of complete remission in adult acute leukemia

Cancer
M J KeatingE J Freireich

Abstract

Two hundred and two adult patients with acute leukemia were analyzed to determine pretreatment and treatment factors that could predict for duration of bone marrow remission. Several factors had a significant effect on remission duration, including morphologic diagnosis (AML greater than ALL greater than AUL), initial blast cell count, age, serum LDH, fibrinogen level, labeling index, and in vitro agar colony growth. Patients who attained a remission quickly or in whom leukemic cells in blood and bone marrow were rapidly cleared had long remissions. After applying regression model fitting methods, the six major factors, in order of significance, were the initial serum LDH level, pretreatment fibrinogen level, the number of courses of treatment to obtain a remission, morphologic diagnosis, the halving rate of leukemic cells in the blood, and the age of the patient. The model derived from this study was applied to the 202 patients and suggested that patients likely to have short or long bone marrow remission can be identified.

References

Mar 5, 1977·Lancet·R P Gale, M J Cline
Jul 23, 1977·Lancet·B A Peterson, C D Bloomfield
Aug 1, 1978·Cancer·E J FreireichT Smith
Mar 1, 1978·Cancer·G H LymanH Urban
Aug 1, 1975·Cancer·B D ClarksonJ H Burchenal
May 1, 1976·The Medical Clinics of North America·J F Holland, J G Bekesi
Oct 1, 1975·British Journal of Cancer·D CrowtherR L Sewell

❮ Previous
Next ❯

Citations

Mar 1, 1993·Journal of Clinical Psychology·D R EvansW B Barton
Jan 1, 1986·Cancer Chemotherapy and Pharmacology·H S DhaliwalT A Lister
Oct 3, 1983·Klinische Wochenschrift·D GereckeW D Hirschmann
Aug 1, 1987·European Journal of Cancer & Clinical Oncology·M van der WeideD A Kester
Sep 1, 1983·The Journal of Clinical Investigation·B BarlogieB Drewinko
Jul 1, 1985·The Journal of Clinical Investigation·H M KantarjianE J Freireich
Jan 11, 1992·Leukemia·M E Nesbit, W G Woods
Jan 1, 1995·Leukemia & Lymphoma·E CacciolaS Impera
Feb 2, 2011·Leukemia & Lymphoma·Fábio R KerbauyNelson Hamerschlak
Feb 4, 2014·British Journal of Haematology·Ruediger LierschUtz Krug
Sep 1, 1985·Cancer Treatment Reviews·S E Bates, D L Longo
Jan 1, 1981·Leukemia Research·B A Peterson, C D Bloomfield
Nov 1, 1987·European Journal of Cancer & Clinical Oncology·A M CarellaM Risso
Sep 1, 1982·European Journal of Cancer & Clinical Oncology·M LazzarinoC Bernasconi
Aug 1, 1989·Statistics in Medicine·R B Davis, J R Anderson
Jun 1, 1989·British Journal of Haematology·F Hau BogardR Zittoun
Dec 1, 1982·Australian and New Zealand Journal of Medicine·C M PatonM G Whiteside
Jan 1, 1987·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·P GinésC Rozman
May 1, 1986·International Journal of Cell Cloning·C PeschelH Braunsteiner
Jan 1, 1983·Medical and Pediatric Oncology·U JehnD Hölzel
May 1, 1983·American Journal of Hematology·M B Van Der WeydenT E Gan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.